We are developing therapeutics that target senescence and adjacent biology with broad application across multiple indications with established endpoints and well-defined regulatory pathways to approval. Our initial focus is on delivering localized therapy in ophthalmologic and neurologic diseases.
UNITY is also pursuing multiple approaches to target novel biology in eye diseases. UBX1325 is a senolytic small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulatory proteins, and is being evaluated for the treatment of age-related diseases of the eye – including diabetic macular edema, diabetic retinopathy, and age-related macular degeneration. The compound targets proteins that senescent cells rely on for survival. A Phase 1 study will explore the initial safety and tolerability of UBX1325 in patients with diabetic macular edema. UBX1967 remains in the portfolio as a molecularly distinct backup to UBX1325.
UNITY is also developing a novel antibody with a unique mechanism of action that activates the Tie2 pathway in age-related eye diseases. The expression of Tie2 decreases with age and leads to the loss of vascular barrier integrity and diseased blood vessel formation in the eye. UNITY’s Tie2 activator, called UBX2050, aims to restore healthy vasculature and function in diabetic macular edema, independent of Bcl-xL inhibition.
UNITY’s neurology programs build upon our foundational cellular senescence research platform to target core features of neurodegenerative diseases and cognitive disorders. These programs will focus on developing senolytic therapies for neurological diseases, as well as exploring novel mechanisms for cognitive benefit.
Our other research programs will also explore therapeutic modalities beyond small molecule approaches to significantly expand the target space for modulating senescent cell biology implicated as drivers of age-related diseases.